Eli Lilly's Orforglipron Study in Adolescents with Obesity Underway
Eli Lilly is conducting a study to evaluate the efficacy and safety of orforglipron in adolescents with obesity or related comorbidities.
Asset / Drug
Drug and asset intelligence for Orforglipron with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.